Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
WAC antisense RNA 1 (WAC-AS1) is a long non-coding RNA (lncRNA) transcribed antisense to the WAC gene at the chromosomal locus 10p12.1. It is part of a class of RNA molecules typically longer than 200 nucleotides that do not encode proteins but regulate gene expression and cellular functions. WAC-AS1 participates in multiple biological processes, especially in cancer, where it is implicated in regulation of tumor proliferation, progression, cell cycle, and glycolysis. It has context-dependent effects: acting as a protective factor in certain cancers (e.g., glioma) and a risk factor in others (e.g., hepatocellular carcinoma). WAC-AS1 also modulates immune cell infiltration and the tumor microenvironment, and plays a role in Hepatitis B virus replication by regulating autophagy pathways. While considered a biomarker for prognosis and disease characterization in some cancers, there is no evidence it is currently a direct target of any approved therapeutic agents
Not directly targeted by drugs; acts as a functional regulator via competing endogenous RNA (ceRNA), influencing microRNAs (e.g., miR-320d, miR-192-5p) and modulating downstream gene expression in cancer and infection
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on WAC antisense RNA 1 (WAC-AS1).